SK44197A3 - Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type - Google Patents
Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type Download PDFInfo
- Publication number
- SK44197A3 SK44197A3 SK441-97A SK44197A SK44197A3 SK 44197 A3 SK44197 A3 SK 44197A3 SK 44197 A SK44197 A SK 44197A SK 44197 A3 SK44197 A3 SK 44197A3
- Authority
- SK
- Slovakia
- Prior art keywords
- sequence
- cells
- peptide
- cell
- idiotypic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11119694A IL111196A0 (en) | 1994-10-07 | 1994-10-07 | Peptides and pharmaceutical compositions comprising them |
| PCT/US1995/012686 WO1996011214A1 (fr) | 1994-10-07 | 1995-10-10 | Peptides et compositions pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK44197A3 true SK44197A3 (en) | 1997-11-05 |
Family
ID=11066614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK441-97A SK44197A3 (en) | 1994-10-07 | 1995-10-10 | Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0783524B1 (fr) |
| JP (1) | JPH10507345A (fr) |
| KR (1) | KR100381711B1 (fr) |
| AT (1) | ATE289611T1 (fr) |
| AU (1) | AU708301B2 (fr) |
| CA (1) | CA2201935A1 (fr) |
| CZ (1) | CZ103197A3 (fr) |
| DE (1) | DE69534024T2 (fr) |
| FI (1) | FI971427A7 (fr) |
| HU (1) | HUT77484A (fr) |
| IL (1) | IL111196A0 (fr) |
| NO (1) | NO971517L (fr) |
| PL (1) | PL319831A1 (fr) |
| SK (1) | SK44197A3 (fr) |
| WO (1) | WO1996011214A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716963B1 (en) | 1998-05-22 | 2004-04-06 | Abbott Laboratories | Peptide antiangiogenic drugs |
| WO2000024770A2 (fr) | 1998-10-23 | 2000-05-04 | Amgen Inc. | Composes thrombopoietiques |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| AU2005289685B2 (en) | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| EP3122768A2 (fr) * | 2014-03-27 | 2017-02-01 | Yeda Research and Development Co. Ltd. | Récepteur de cellules t cdr3, peptides et anticorps |
| WO2015153912A1 (fr) | 2014-04-03 | 2015-10-08 | Igm Biosciences, Inc. | Chaîne j modifiée |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| HK1252791A1 (zh) | 2015-09-30 | 2019-06-06 | Igm Biosciences, Inc. | 具有经修饰的j链的结合分子 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4886743A (en) * | 1985-04-24 | 1989-12-12 | California Institute Of Technology | Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof |
-
1994
- 1994-10-07 IL IL11119694A patent/IL111196A0/xx unknown
-
1995
- 1995-10-10 CZ CZ971031A patent/CZ103197A3/cs unknown
- 1995-10-10 HU HU9800152A patent/HUT77484A/hu unknown
- 1995-10-10 KR KR1019970702283A patent/KR100381711B1/ko not_active Expired - Fee Related
- 1995-10-10 DE DE69534024T patent/DE69534024T2/de not_active Expired - Lifetime
- 1995-10-10 CA CA002201935A patent/CA2201935A1/fr not_active Abandoned
- 1995-10-10 EP EP95937323A patent/EP0783524B1/fr not_active Expired - Lifetime
- 1995-10-10 FI FI971427A patent/FI971427A7/fi unknown
- 1995-10-10 AT AT95937323T patent/ATE289611T1/de active IP Right Revival
- 1995-10-10 WO PCT/US1995/012686 patent/WO1996011214A1/fr not_active Ceased
- 1995-10-10 PL PL95319831A patent/PL319831A1/xx unknown
- 1995-10-10 AU AU39462/95A patent/AU708301B2/en not_active Ceased
- 1995-10-10 SK SK441-97A patent/SK44197A3/sk unknown
- 1995-10-10 JP JP8512640A patent/JPH10507345A/ja active Pending
-
1997
- 1997-04-03 NO NO971517A patent/NO971517L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO971517D0 (no) | 1997-04-03 |
| EP0783524A4 (fr) | 2000-05-17 |
| HUT77484A (hu) | 1998-05-28 |
| FI971427L (fi) | 1997-05-26 |
| AU3946295A (en) | 1996-05-02 |
| JPH10507345A (ja) | 1998-07-21 |
| FI971427A0 (fi) | 1997-04-04 |
| CZ103197A3 (en) | 1997-09-17 |
| KR970706306A (ko) | 1997-11-03 |
| DE69534024T2 (de) | 2006-01-12 |
| EP0783524A1 (fr) | 1997-07-16 |
| ATE289611T1 (de) | 2005-03-15 |
| WO1996011214A1 (fr) | 1996-04-18 |
| NO971517L (no) | 1997-05-22 |
| IL111196A0 (en) | 1994-12-29 |
| AU708301B2 (en) | 1999-07-29 |
| PL319831A1 (en) | 1997-09-01 |
| EP0783524B1 (fr) | 2005-02-23 |
| FI971427A7 (fi) | 1997-05-26 |
| DE69534024D1 (de) | 2005-03-31 |
| CA2201935A1 (fr) | 1996-04-18 |
| KR100381711B1 (ko) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2400249T3 (es) | Vacunas recombinantes y utilización de las mismas | |
| US7704970B2 (en) | DNA vaccination for treatment of autoimmune disease | |
| AU2002341266B2 (en) | Use of HMGB1 for the activation of dendritic cells | |
| US5939400A (en) | DNA vaccination for induction of suppressive T cell response | |
| PT1249490E (pt) | Activação de células t citotóxicas in vitro | |
| KR100400480B1 (ko) | 펩티드p277유사체들,그들을포함하는당뇨병의치료또는진단을위한약제학적조성물들및키트 | |
| AU651350B2 (en) | Multiple sclerosis T-cell receptor | |
| US6096314A (en) | Peptides and pharmaceutical compositions comprising them | |
| CA2110055C (fr) | Utilisation de peptides du recepteur de lymphocytes t contre les maladies du systeme immunitaire | |
| SK44197A3 (en) | Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type | |
| Raju et al. | T cell recognition of human pre-proinsulin peptides depends on the polymorphism at HLA DQ locus: a study using HLA DQ8 and DQ6 transgenic mice | |
| CA2133749A1 (fr) | Suppression de la proliferation de lymphocytes t a l'aide de fragments peptidiques de la proteine de base de la myeline | |
| CN101316610A (zh) | T细胞受体恒定区的免疫原性片段及其衍生的肽 | |
| CA2363269C (fr) | Vaccination par adn pour le traitement de maladies auto-immunes | |
| AU2003232751A1 (en) | Immunoglobulin conjugates of autoantigens and their use in the prevention of disease | |
| JP2005528910A (ja) | T細胞レセプターcdr3配列および検出のための方法 | |
| KR20030086983A (ko) | 티 세포 리셉터 브이 베타 - 디 베타 - 제이 베타 서열과그것을 검출하는 방법 | |
| KR20050016491A (ko) | 티세포 수용체 씨디알3 서열 및 검출방법 | |
| Sarukhan et al. | An Analysis of T cell receptor diversity in the NOD mouse: What can it tell us about the autoimmune process? | |
| Sercarz | Encephalitogenic Epitopes of Myelin | |
| BG63183B2 (bg) | Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации | |
| BG62348B2 (bg) | Ваксиниране чрез специфични т-клетъчни популации срещу заболявания в резултат на патогенни отговори | |
| BG63182B2 (bg) | Ваксиниране чрез специфични т- клетъчни популации срещу заболявания в резултат на патогенни отговори |